Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

CompareNetworks is proud to announce the publication of the first issue of Cell & Gene Therapy Review, marking a significant ...

High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all ...

High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4 ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...

A new type of bone marrow transplant can cure sickle cell disease with only half of the donor's cell proteins matching, ...

Hyderabad: Cell and gene therapy solutions provider Miltenyi Biotec on Monday announced the roll-out of what is touted as ...

Sensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its ...